New Delhi, April 15 (BNP) – The two-day India Pharma 2026 summit concluded with a strong call for increased funding, improved infrastructure and faster execution to drive innovation in India’s pharmaceutical sector.
Organised by the Department of Pharmaceuticals in partnership with industry bodies, the event brought together over 800 delegates and more than 60 speakers across 10 sessions to discuss the future of India’s pharma and biopharma ecosystem.
Discussions on the second day focused on building a robust financing ecosystem, with stakeholders highlighting the need for diverse funding sources such as venture capital, private equity and public-private partnerships to support high-risk, long-cycle research and development.
In the valedictory session, officials emphasised three key enablers for future growth—funding, infrastructure and speed—stressing that coordinated action between government, industry and academia will be critical for global competitiveness.
Industry leaders also called for a shift from volume-driven growth to innovation-led development, focusing on advanced therapeutics and cutting-edge research. The discussions underscored the importance of stronger collaboration, improved market access and sustained investment in R&D.
Participants noted that while India has built a strong base in generics and vaccines, the next phase will depend on its ability to scale innovation and position itself as a global leader in new drug development.
Leave a Reply